commentaires sur les principaux essais cliniques pr sent s l esc 2009 n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Commentaires sur les principaux essais cliniques présentés à l’ESC 2009 PowerPoint Presentation
Download Presentation
Commentaires sur les principaux essais cliniques présentés à l’ESC 2009

Loading in 2 Seconds...

play fullscreen
1 / 20

Commentaires sur les principaux essais cliniques présentés à l’ESC 2009 - PowerPoint PPT Presentation


  • 117 Views
  • Uploaded on

Commentaires sur les principaux essais cliniques présentés à l’ESC 2009. Damien Coisne. Différentes voies d’inhibition= différentes voies de recherche. PLATO Lars Vallentin. Perspective Clopidogrel Prasugrel Ticagrelor. Rapidité d’action Variabilité interindividuelle Reversibilité

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Commentaires sur les principaux essais cliniques présentés à l’ESC 2009' - ardith


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
commentaires sur les principaux essais cliniques pr sent s l esc 2009

Commentaires sur les principaux essais cliniques présentés à l’ESC 2009

Damien Coisne

plato lars vallentin
PLATO Lars Vallentin

Perspective

Clopidogrel

Prasugrel

Ticagrelor

Rapidité d’action

Variabilité interindividuelle

Reversibilité

Risque hémorragique

Efficacité clinique

Albert Schoming Editorial NEJM 2009, 361,11, 1108

slide7

Le progression de CURE vers TRITON s’est accompagné d’un augmentation du risque hémorragique Pas dans le cas de PLATO

slide8

CURE et Triton: pas de réduction de la mortalité globale, Ici réduction (mais étude non dimensionnée pour) mais effet très probable.

Les “nouveaux” effets secondaires découverts par PLATO: dyspnée,bradyarythmie,élévation créat, ac urique!!!!!

slide9

Is CURE a Cure for Acute Coronary Syndromes? Statistical Versus Clinical Significance Editorial U Khot JACC 2002

These are not trivial risks. If clopidogrel is administered

to 1,000 patients with ACS to prevent 15 nonfatal MIs, 10

additional patients develop major bleeding, 69 additional

patients have minor bleeding, and 200 patients have surgical decisions complicated by its administration. In addition, 978 patients taking clopidogrel derive no significant benefit from this drug, and all of this occurs without saving one life.

commentaires
Commentaires

Essai relativement court: 1 an

Dose de charge du Clopidogrel: 600 mg pout tous

Reduction de l’interaction potentielle avec l’omeprazole

Apects Pratiques potentiels

Ticagrelor a utiliser en cas de chirugie très probable.

Le s SCA en attente de chirurgie

Prudence en cas d’ins respiratoire chronique, ins rénale??

Quid des patients à faible compliance potentielle ( essai thérapeutique vs vraie vie)

Albert Schoming Editorial NEJM 2009, 361,11, 1108

slide11

ATLAS

Coagulation Cascade

TF (Tissue Factor)

XIa

XI

IX

IXa

VIIa + TF

VII

Extrinsic Pathway

Intrinsic Pathway

VIIIa

X

Xa

Va

Dabigatran

Rivaroxaban

IIa (Thrombin)

II

ATLAS

Fibrinogen

Fibrin

Gibson CM, AHA 2008

slide15
Rely

J Connolly NEJM Sept 2, 361

Editorial

Can we rely on RELY

B Gage NEJM Sept 2, 361

slide16

In patients with atrial fibrillation, warfarin prevents 64% of strokes.

  • Despite clear and consistent recommendations, warfarin is prescribed to only two thirds of appropriate candidates
  • After conversion to its active form,dabigatran competitively inhibits thrombin.
  • The quality of warfarin management in RELY was assessed by measuring the percentage of time (excluding the first week of therapy) during which the INR was within the therapeutic range, which averaged 64%. (Similar to ACTIVE trial).
  • RE-LY participants who were randomly assigned to receive warfarin would have needed to have an INR within the therapeutic range approximately 79% of the time to have a stroke rate as low as that in the group receiving 150 mg of dabigatran

Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant

over antiplatelet therapy in atrial fibrillation depends

on the quality of international normalized ratio control achieved

by centers and countries as measured by time in therapeutic

range. Circulation 2008;118:2029-37.

effets secondaires interactions
Effets secondaires interactions
  • In RE-LY, rates of dyspepsia (including abdominal pain) were elevated with dabigatran (11.8% in the 110-mg group and 11.3% in the 150-mg group).
  • Dabigatran is not without important drug interactions P-glycoprotein inhibitors — including verapamil, amiodarone, and especiallyquinidine
  • Which dose for elderly patients, renal impairement (patients with CR cl less than 30ml/mn were excluded)
slide19

To prevent one nonhemorrhagic stroke, the number of patients who would need to be treated with dabigatran at a dose of 150 mg twice daily, rather than warfarin, is approximately 357.

  • The rates of hemorrhagic stroke with the 110mg and 150-mg dabigatran doses (0.12% and 0.10%) were significantly lower than that with warfarin (0.38%).